Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer

OBJECTIVE: To determine the safety and clinical efficacy of two anti-angiogenic agents, bevacizumab and lenalidomide, with docetaxel and prednisone. PATIENTS AND METHODS: Eligible patients with metastatic castration-resistant prostate cancer enrolled in this open-label, phase II study of lenalidomid...

詳細記述

保存先:
書誌詳細
出版年:BJU Int
主要な著者: Madan, Ravi A., Karzai, Fatima H., Ning, Yang-Min, Adesunloye, Bamidele A., Huang, Xuan, Harold, Nancy, Couvillon, Anna, Chun, Guinevere, Cordes, Lisa, Sissung, Tristan, Beedie, Shaunna L., Dawson, Nancy A., Theoret, Marc R., McLeod, David G., Rosner, Inger, Trepel, Jane B., Lee, Min-Jung, Tomita, Yusuke, Lee, Sunmin, Chen, Clara, Steinberg, Seth M., Arlen, Philip M., Gulley, James L., Figg, William D., Dahut, William L.
フォーマット: Artigo
言語:Inglês
出版事項: 2016
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6387685/
https://ncbi.nlm.nih.gov/pubmed/26780387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bju.13412
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料